Core Viewpoint - Fosen Pharmaceutical (01652) shares rose over 7% following the approval of its hypertension treatment, "Mei Asha Tan Potassium Tablets," by the National Medical Products Administration of China [1] Company Summary - Fosen Pharmaceutical's subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., developed "Mei Asha Tan Potassium Tablets," which have received regulatory approval for the treatment of primary hypertension [1] - The active ingredient, Mei Asha Tan Potassium, is an angiotensin II receptor antagonist that converts rapidly to the active component Azilsartan upon oral absorption, effectively lowering blood pressure by blocking the angiotensin II hormone [1] Industry Summary - The "sartan" class of antihypertensive drugs holds over 80% market share in the overall renin-angiotensin system (RAS) market, with sales exceeding 100 billion RMB in 2022 [1] - "Sartan" medications play a crucial role within the family of antihypertensive drugs, indicating strong market demand and potential for growth in this segment [1]

Core Viewpoint - Fosen Pharmaceutical (01652) shares rose over 7% following the approval of its hypertension treatment, "Mei Asha Tan Potassium Tablets," by the National Medical Products Administration of China [1] Company Summary - Fosen Pharmaceutical's subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., received approval for "Mei Asha Tan Potassium Tablets," which are indicated for the treatment of primary hypertension [1] - The active ingredient, Mei Asha Tan Potassium, is an angiotensin II receptor antagonist that converts rapidly to the active component Azilsartan upon oral absorption, effectively lowering blood pressure by blocking the angiotensin II hormone [1] Industry Summary - The "sartan" class of antihypertensive drugs holds over 80% market share in the overall renin-angiotensin system (RAS) market, with sales exceeding 100 billion RMB in 2022 [1] - "Sartan" drugs play a crucial role within the family of antihypertensive medications, indicating strong market demand and potential for growth in this segment [1]

Core Insights - The company has received approval from the National Medical Products Administration of China for its product "Mebsartan Potassium Tablets" (trademark: Kuanopeng), which is indicated for the treatment of primary hypertension [1][2] - "Mebsartan Potassium" is a significant addition to the company's product pipeline in the cardiovascular system sector, providing more treatment options for adult patients with primary hypertension [2] Group 1: Product Details - "Mebsartan Potassium" is an angiotensin II receptor antagonist that converts rapidly to its active form, Azilsartan, after oral administration, effectively lowering blood pressure by blocking angiotensin II hormone [1] - The product is classified as a Category B drug by the National Medical Insurance Administration, with no restrictions on insurance indications or disease types, making it a first-line antihypertensive medication for adults [1] Group 2: Market Context - The "sartan" class of antihypertensive drugs holds over 80% market share in the overall renin-angiotensin system (RAS) market, with sales exceeding 10 billion RMB in 2022, highlighting its importance in the hypertension drug family [1] - The company’s "Mebsartan Potassium Tablets" are available in 40mg and 80mg dosages, catering to both mild to moderate and severe hypertension patients [2]

在整体肾素—血管紧张素系统(RAS)市场中，有超过80%的份额被"沙坦"类单一及各类联合疗法用药占 据，2022年销售额超100亿元人民币，"沙坦"类降压药在整个高血压药物家族中占据重要位置。 "美阿沙坦钾片"的主要成分美阿沙坦钾属于血管紧张素II受体拮抗剂，口服吸收后迅速转化为活性成分 阿齐沙坦，可通过阻断血管紧张素II荷尔蒙而起到降压的作用。 "美阿沙坦钾片"是国家医疗保障局乙类药物，且无医保适应症及病种限制，目前已成为国内外治疗成人 原发性高血压的一线降压药物。其具有降压效果显著;降压作用持久、稳定;器官保护作用更强等优势。 我公司开发的"美阿沙坦钾片"，与原研剂型一致，通过药学和临床(BE)研究达到其品质和疗效与参比制 剂一致，保障患者用药安全、有效，风险—获益比与参比制剂相当。 福森药业(01652)发布公告，本集团的全资附属公司嘉亨(珠海横琴)医药科技有限公司研发的"美阿沙坦 钾片"(商标：快诺平)，上市申请已获得中国国家药品监督管理局批准，批准用于原发性高血压的治 疗。 "美阿沙坦钾片"是本集团又一重要产品，进一步丰富了本集团在血液循环系统领域的医疗产品管线。 40mg和80mg两种规格，可分别 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1652） 自願公告 「美阿沙坦鉀片」獲批上市 福森藥業有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」） 欣然宣佈，本集團之全資附屬公司嘉亨（ 珠海橫琴 ）醫藥科技有限公司研發的「美 阿 沙 坦 鉀 片」（ 商 標 ： 快 諾 平 ）， 上 市 申 請 已 獲 得 中 國 國 家 藥 品 監 督 管 理 局 批 准 ， 批准用於原發性高血壓的治療。 「美阿沙坦鉀片」的主要成分美阿沙坦鉀屬於血管緊張素II受體拮抗劑，口服吸收 後迅速轉化為活性成分阿齊沙坦，可通過阻斷血管緊張素II荷爾蒙而起到降壓的 作用。 – 1 – 「美阿沙坦鉀片」是本集團又一重要產品，進一步豐富了 ...

Policy Developments - Shanghai has announced a reduction in prices for certain medical services, including continuous dynamic blood glucose monitoring, effective from October 15, 2025 [2] Drug and Device Approvals - Humanwell Healthcare's Dapoxetine Hydrochloride Tablets received a drug registration certificate, with projected national sales of approximately 1.1 billion yuan for 2024 [4] - Anglikon has received a drug registration certificate for its Amlodipine Besylate Tablets, aimed at treating primary hypertension in adults [5] - David Medical's subsidiary has obtained a medical device registration for a portable electronic endoscope image processor, enhancing endoscopic diagnostics [6] - The National Medical Products Administration approved the listing of Momelotinib Tablets, providing a new treatment option for moderate to severe plaque psoriasis [7] - Hengrui Medicine's subsidiary received clinical trial approval for SHR-1905 injection, a monoclonal antibody targeting inflammatory cytokines, with a similar product projected to generate approximately 1.22 billion USD in global sales for 2024 [8] - Lingbei's investigational drug Bexicaserin has been recognized as a breakthrough therapy for developmental epileptic encephalopathy-related seizures [15] Capital Market Activities - Four Seasons Pharmaceutical's trustee purchased a total of 10 million shares under a share incentive plan at an average price of approximately 1.619 HKD per share [10] - Jiuan Medical plans to repurchase shares worth no less than 300 million yuan and no more than 600 million yuan, with a maximum repurchase price of 53.5 yuan per share [11] Industry Developments - The Shanghai High-end Medical Device Cluster was officially launched, aiming to achieve over 500 new domestic Class III medical device registrations and over 100 overseas approvals by 2027 [13] - Boehringer Ingelheim announced the local production plan for its diabetes drug Otonil, with an investment of over 5 billion yuan in R&D over the next five years [14] Financial Disclosures - Boteng Co. expects a net profit of 73.2 million to 88.2 million yuan for the first three quarters of 2025, marking a turnaround from losses, with revenue growth of 17% to 21% [17] - Saintno Bio anticipates a net profit increase of 100.53% to 145.10% for the first three quarters of 2025, driven by stable business growth and increased demand for peptide raw materials [19]

Group 1 - Warner Pharmaceuticals received the drug registration certificate for polyethylene glycol sodium potassium powder, which is indicated for the treatment of chronic constipation and fecal impaction [1] - The approval of the drug registration certificate enriches the company's formulation product variety and positively impacts the optimization of the product structure [1] - Warner Pharmaceuticals reported a revenue of 714 million yuan for the first half of 2025, a year-on-year decrease of 3.37%, with a net profit attributable to shareholders of 71 million yuan, down 36.95% [1] Group 2 - Renfu Pharmaceutical announced that its subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., received the drug registration certificate for dapoxetine hydrochloride tablets, which are used to treat premature ejaculation [2] - The total sales of dapoxetine hydrochloride tablets in 2024 are estimated to be around 1.1 billion yuan, with major manufacturers including Shandong Huabo Kaisheng Biotechnology Co. and Sichuan Kelun Pharmaceutical Co. [2] - Anglikon received the drug registration certificate for azilsartan potassium tablets, which are indicated for the treatment of primary hypertension in adults [3] - Xinhua Pharmaceutical announced the approval of fumarate bisoprolol tablets, indicated for hypertension and chronic stable heart failure with reduced left ventricular function [3]

Core Viewpoint - Zhejiang Anglikang Pharmaceutical Co., Ltd. has received the drug registration certificate for Measartan Potassium Tablets from the National Medical Products Administration, which is expected to enhance the company's product pipeline and market presence [1] Group 1: Product Approval - The drug Measartan Potassium Tablets has been approved in two specifications: 40mg and 80mg [1] - The approval number is valid until September 29, 2030, indicating a long-term market presence [1] - The drug is indicated for the treatment of adult primary hypertension, addressing a significant health issue [1] Group 2: Market Impact - The approval is considered equivalent to passing the consistency evaluation, which may positively influence the company's market competitiveness [1] - The company received the acceptance notice for this drug in 2024, suggesting a proactive approach to expanding its product offerings [1] Group 3: Industry Considerations - The pharmaceutical industry is subject to various factors such as policies and market dynamics, which can impact drug sales and overall performance [1] - The company has advised investors to remain cautious regarding potential risks associated with the pharmaceutical market [1]

Core Viewpoint - The pilot program granting public health physicians prescription rights in Guangdong aims to enhance the integration of medical and preventive services, particularly for chronic disease management [2][4]. Group 1: Implementation of Prescription Rights - The first public health physician prescription in Zhongshan was issued on August 19, coinciding with China's Physician Day, marking a significant step in the pilot program [1]. - A total of 20 public health physicians in Zhongshan are now authorized to prescribe for 18 specific diseases, including diabetes and hypertension, across five community health service centers and three medical institutions [2][4]. Group 2: Benefits for Patients - Patients like Jiang Dandan have reported significant time savings, with the ability to receive prescriptions directly from public health physicians, reducing the need for lengthy hospital visits [3]. - The new prescription rights allow public health physicians to provide a complete service loop for chronic disease management, including follow-up, assessment, guidance, and medication [4]. Group 3: Broader Implications for Public Health - The initiative is expected to improve the continuity and coordination of care for chronic disease patients, addressing the challenges faced by public health physicians who previously could not prescribe medications [5]. - The program aims to create an integrated model of disease prevention and management, enhancing the overall effectiveness of public health services [5].

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. is expected to report a net loss of 38 million to 45 million yuan for the first half of 2025, a significant decline from a profit of 62.89 million yuan in the same period last year, primarily due to a substantial monopoly fine and industry challenges [2][3][4]. Financial Performance - The company's net profit for the first half of 2025 is projected to decline by 101 million to 108 million yuan year-on-year, marking a reversal from profit to loss [3][4]. - In Q1 2025, the company experienced an 18.78% increase in revenue, but net profit fell by 29.15%, indicating a situation of "increased revenue but decreased profit" [3][4]. - The expected non-recurring net profit for the first half of 2025 is estimated to be between 18.5 million and 22 million yuan, reflecting a year-on-year decrease of 63.98% to 69.71% [4][12]. Regulatory Issues - The company was fined a total of 61.0382 million yuan for price manipulation of dexamethasone phosphate sodium raw materials, which accounted for 72.53% of its net profit for 2024 [4][5]. - The fine includes the confiscation of illegal gains of 17.8992 million yuan and a penalty based on 8% of the 2023 sales [4][5]. Market Dynamics - The pharmaceutical industry is experiencing a clear divide, with some companies achieving stable growth through innovation, while generic drug companies like Lianhuan are facing significant pressure from price reductions due to national drug procurement policies [5][6]. - The price of dexamethasone phosphate sodium has plummeted from 98.76 yuan per unit during the monopoly period to between 0.23 and 4.5 yuan post-procurement [5][6]. Transformation Efforts - Lianhuan is actively pursuing transformation by focusing on innovative drug development, with particular attention on the SGLT2 inhibitor LH-1801, which is expected to enter the market in 2026 [10][11]. - The company has seen a continuous increase in R&D investment, reaching 277 million yuan in 2024, which is 12.82% of its revenue [11][12]. Financing Strategies - The company plans to issue up to 500 million yuan in technology innovation bonds to support new drug development and optimize its debt structure [12][13].